Table 1

Effect of cholinergic modulation on fasting antroduodenal manometry and electrogastrography

Prestudy drugPoststudy drug
Antral manometryDuodenal MI (ln units)EGG dominant frequency (cpm)Antral manometryDuodenal MI (ln units)EGG dominant frequency (cpm)EGG power ratio
Frequency (cpm)Amplitude (mm Hg)MI
(ln units)
Frequency (cpm)Amplitude (mm Hg)MI
(ln units)
Placebo1.4 (0.3)29 (3)4.7 (0.4)4.7 (0.2)2.8 (0.1)1.6 (0.3)30 (5)4.8 (0.5)4.2 (0.5)2.7 (0.1)0.95 (0.38)
Atropine1.2 (0.4)35 (4)4.9 (0.3)4.5 (0.5)2.8 (0.1)0.3 (0.2)* 10 (3)* 1.5 (0.6)* 2.2 (0.7)* 2.8 (0.1)0.71 (0.15)*
Bethanechol1.3 (0.4)34 (8)4.7 (0.5)3.7 (0.7)2.8 (0.1)1.8 (0.2)39 (3)* 5.6 (0.1)* 4.5 (0.3)* 2.7 (0.1)5.9 (2.1)*
  • Results expressed as mean (SEM). *p<0.05 versus prestudy drug using paired Student’s t test.

  • Electrogastrography (EGG) power ratio in this table is the ratio of the power of the dominant frequency after study drug administration divided by the power of the dominant frequency before study drug administration.

  • MI, motility index; DAS, dynamic antral scintigraphy.